NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
Nilo Therapeutics
United States
- New York City
- 10/10/2025
- Series A
- $101,000,000
Nilo Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.
- Industry Biotechnology Research
- Website https://www.nilotx.com/
- LinkedIn https://www.linkedin.com/company/nilo-therapeutics/
Related People
Kim Seth, Ph.D.Founder
United States -
Greater Boston
25+ years leadership experience in Biopharma:
* Start-up pre-Series A through IPO
* Big Pharma strategy and R&D operations
* Therapeutics discovery and development
* Oncology, Neuroscience, Immunology
* Company building and financing
* Corporate Development
* Strategy & Operations
* Wall Street analyst/ Capital Markets
* Licensing: buy- and sell-side
* Investment Analysis
* Valuation
* Search & Evaluation
* Market analysis and CI
* Mergers & Aquisitions (M&A)
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)